(32) conducted ctDNA BRCA1 and BRCA2 reversal mutation testing in 78 patients with epithelial ovarian cancer prior to PARP inhibitor therapy, identifying eight patients with reversal mutations, whose progression-free survival (PFS) was significantly lower than that of patients without such mutations. The gene discussed is BRCA1; the disease is ovarian carcinoma.